Stockscreener 앱 받기
14.90
5.97%
0.84
시간 외 거래:
14.81
-0.09
-0.60%
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Brokers Issue Forecasts for CAPR FY2025 Earnings - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone - Yahoo Finance
When the Price of (CAPR) Talks, People Listen - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 53% CAGR over 5 years, surging 8.8% in the last week alone - Simply Wall St
Krilogy Financial LLC Makes New $287,000 Investment in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Barclays PLC Has $552,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Barclays PLC Buys 18,724 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade - MSN
Will Capricor's Deramiocel Make History As The First Approved Treatment For DMD Cardiomyopathy? - RTTNews
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Growth in Short Interest - MarketBeat
Dilated Cardiomyopathy Pipeline Overview 2024: FDA Approvals and Key Developments | Vericel Corporation, AstraZeneca, Pfizer, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics - The Globe and Mail
Certain Common Stock of Capricor Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2025. - Marketscreener.com
Capricor's CAP-1002: A New Hope For Duchenne Muscular Dystrophy? - RTTNews
Application finalized for DMD cell therapy CAP-1002, now deramiocel - Muscular Dystrophy News
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA - MSN
Capricor Therapeutics Completes BLA Submission for Deramiocel Treatment of Duchenne Muscular Dystrophy - Defense World
CAPR Stock Up On Completion Of Rolling Submission Of DMD Drug BLA - Barchart
Capricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Capricor stock reiterated at Buy at H.C. Wainwright By Investing.com - Investing.com Canada
Capricor Therapeutics Stock Surges On BLA Submission for Cell Therapy To Treat Muscular Dystrophy: Retail’s Excited - MSN
Capricor files cell therapy for DMD cardiomyopathy with FDA - pharmaphorum
Capricor completes U.S. marketing submission for lead candidate - MSN
Capricor completes BLA submission for deramiocel - The Pharma Letter
Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock - Benzinga
HC Wainwright Reaffirms "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor seeks U.S. marketing nod for DMD drug (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy - The Manila Times
Capricor completes FDA submission for DMD therapy By Investing.com - Investing.com Canada
Capricor Therapeutics Completes Submission of Biologics - GlobeNewswire
(CAPR) Trading Report - Stock Traders Daily
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Increase in Short Interest - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 26.8% in December - MarketBeat
Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50 - Defense World
State Street Corp Has $7.79 Million Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $34.50 - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 2.9%What's Next? - MarketBeat
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
Capricor Therapeutics (NASDAQ:CAPR) Trading 5.6% HigherWhat's Next? - MarketBeat
(CAPR) Trading Advice - Stock Traders Daily
Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com
The Manufacturers Life Insurance Company Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update - MarketBeat
BNP Paribas Financial Markets Buys 15,872 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 5.3%Here's Why - MarketBeat
Capricor Therapeutics (CAPR) Stock Drops Amid Volatile Biotech Sector - GuruFocus.com
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead - MarketWatch
Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding - Simply Wall St
(CAPR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
250,204 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Point72 Asset Management L.P. - MarketBeat
1.44%
7.27%
자본화:
|
볼륨(24시간):